# Phase II Study of Monoclonal Antibody ch14.18/CHO Continuous Infusion in Patients With Primary Refractory or Relapsed Neuroblastoma

> **NCT02743429** · PHASE2 · UNKNOWN · sponsor: **University Medicine Greifswald** · enrollment: 40 (actual)

## Conditions studied

- Neuroblastoma

## Interventions

- **DRUG:** dinutuximab beta

## Key facts

- **NCT ID:** NCT02743429
- **Lead sponsor:** University Medicine Greifswald
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-03-27
- **Primary completion:** 2023-12
- **Final completion:** 2024-06
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2021-10-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02743429

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02743429, "Phase II Study of Monoclonal Antibody ch14.18/CHO Continuous Infusion in Patients With Primary Refractory or Relapsed Neuroblastoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02743429. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*